Table 3.
Odds ratio (ORs) and 95% confidence interval (CIs) for treatment tolerance and treatment efficacy by meeting physical activity guidelines.
| Meeting guidelines of 7.5 MET-hrs/wk or more of exercise | ||
|---|---|---|
| No | Yes | |
| Total tumors (n=180) | ||
| *Chemotherapy completion (n=153) | ||
| No. population | 76 | 77 |
| No. cases (%) | 59 (77.6) | 56 (72.7) |
| OR (95% CI)a | 1.00 (reference) | 0.91 (0.37, 2.26) |
| *Dose delay (n=140) | ||
| No. population | 71 | 69 |
| No. cases, n (%) | 21 (29.6) | 25 (36.2) |
| OR (95% CI)a | 1.00 (reference) | 1.19 (0.50, 2.79) |
| pCR (ypT0 ypN0) (n=180) | ||
| No. population | 89 | 91 |
| No. cases, n (%) | 19 (21.3) | 26 (28.6) |
| OR (95% CI)a | 1.00 (reference) | 1.29 (0.56, 2.97) |
| HR+ tumors (n=112) | ||
| No. population | 58 | 54 |
| pCR (ypT0 ypN0), n (%) | 6 (10.3) | 13 (24.1) |
| OR (95% CI)b | 1.00 (reference) | 2.46 (0.73, 8.24) |
| HR- tumors (n=67) | ||
| No. population | 30 | 37 |
| pCR (ypT0 ypN0), n (%) | 13 (43.3) | 13 (35.1) |
| OR (95% CI)b | 1.00 (reference) | 0.65 (0.19, 2.17) |
| HER2+ tumors (n=59) | ||
| No. population | 31 | 28 |
| pCR (ypT0 ypN0), n (%) | 10 (32.3) | 9 (32.1) |
| OR (95% CI)b | 1.00 (reference) | 0.60 (0.11, 3.17) |
| HER2- tumors (n=114) | ||
| No. population | 53 | 61 |
| pCR (ypT0 ypN0), n (%) | 8 (15.1) | 16 (26.2) |
| OR (95% CI)b | 1.00 (reference) | 1.93 (0.68, 5.52) |
MET=metabolic equivalent task, OR=odds ratio, CI=confidence interval, pCR=pathological complete response, HR=hormone receptor, HER2= human epidermal growth factor receptor 2
*
Missing: chemotherapy completion n=27 (15.0%), dose delay n=40 (22.2%)
a
Adjusted for age at diagnosis, BMI, race/ethnicity, alcohol intake, menopause status, hormone replacement therapy use, tumor stage, tumor receptor status, and receiving neoadjuvant biological therapy.
b
Adjusted for age at diagnosis, BMI, race/ethnicity, alcohol intake, menopause status, hormone replacement therapy use, and tumor stage.